Project Grant R01HL181419
Award Date 6/15/26
Completion Date 3/31/30
Dollars Obligated $556K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Kansas City, KS 66160, USA
Similar Awards
- Federal Project Grant Award Summary Oregon Health & Science University (OHSU) received a $328,752 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 15, 2025, with completion targeted for June 30, 2030. The research project investigates the role of coagulation factors—specifically plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (TPA), tissue factor pathway...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2.14 million Project Grant to the University of Pennsylvania effective August 22, 2025, through April 30, 2030, under the Cardiovascular Diseases Research program (CFDA 93.837). This award funds fundamental and translational research investigating the mechanisms of placental vascular growth, specifically examining the roles of vascular endothelial growth factor receptor 1 (VEGFR1) and thrombin...
- Federal Project Grant Award Summary Yale University received a $806,978 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025, with a completion date of June 30, 2030. The award funds research investigating Plasminogen Activator Inhibitor 1 (PAI-1) as a therapeutic target for maternal endothelial dysfunction in preeclampsia. The research aims to develop novel therapeutic strategies...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research program (CFDA 93.837), awarded The Johns Hopkins University a Project Grant of $638,176 (awarded May 1, 2026; completion February 28, 2029) to investigate thrombospondin-1 (TSP-1) as a therapeutic target for heart failure with preserved ejection fraction (HFPEF). The research deliverables include mechanistic studies examining how TSP-1 modulates transforming...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Johns Hopkins University a $197,259 Project Grant (CFDA 93.837: Cardiovascular Diseases Research) effective August 1, 2025 through July 31, 2030 to conduct research defining the mechanism of complement pathway activation during pregnancy and its role in adverse pregnancy outcomes in sickle cell disease (SCD). The research will employ the Bioluminescent Modified HAM (BMHAM), a novel functional...
- Federal Project Grant Award Summary Vanderbilt University Medical Center received a $1.77 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded June 10, 2026, with completion targeted for March 31, 2030. The grant funds research into TBX4-driven pulmonary hypertension (PH), the second most common cause of heritable pulmonary arterial hypertension (PAH), which predominantly affects pediatric...
- Summary of Federal Project Grant Award The University of Texas Southwestern Medical Center received a $143,461 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) for the period April 1, 2026 through March 31, 2028. The award funds high-resolution phenotyping research examining the hemodynamic consequences of thoracic endovascular aortic repair (TEVAR) in adults with descending thoracic aortic aneurysm (TAA)....
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of New Mexico Health Sciences Center a Project Grant of $586,637 (awarded September 1, 2025, with completion by August 31, 2027) under the Cardiovascular Diseases Research program (CFDA 93.837) to support basic research on immune dysfunction in hypoxic pulmonary hypertension. The research project will investigate the mechanisms by which chronic hypoxia causes immune dysregulation...
- Federal Grant Award Summary The University of Kansas Medical Center Research Institute, Inc. received a $774,997 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025 through May 31, 2029. The award funds research investigating the contribution of medullary pre-sympathetic neurons to breathing disorders and autonomic dysfunction in heart failure with preserved ejection fraction...
- Federal Project Grant Award Summary Kaiser Foundation Hospitals' Kaiser Foundation Research Institute received a $751,124 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) awarded on September 15, 2025, with completion targeted for June 30, 2030. The grant funds research investigating optimal physical activity (PA) timing, intensity, and 24-hour activity composition for the prevention of hypertensive...